IDH1 and central nervous system cancer: The results showed that certain features, presented as significant metabolites, are dominant in the characteristics of gliomas and appear as differentiators of both IDH/no-IDH, deletion/no-deletion, and low-/high-grade-malignancy (e.g., threonine) mutants.